PCMH
AVBP icon

Polymer Capital Management (HK)’s ArriVent BioPharma AVBP Stock Holding History

Polymer Capital Management (HK)’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-122,276
Closed -$2.82M – 213
2026
Q1 		$2.82M Buy
+122,276
New +$2.76M 0.24% 59

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Polymer Capital Management (HK)'s AVBP Position: Q2 2026 in Review

Polymer Capital Management (HK) sold out of ArriVent BioPharma (AVBP) in Q2 2026, closing a stake of 122,276 shares — an estimated $2.82M sold.

Polymer Capital Management (HK) first reported a position in AVBP in Q1 2026 and held it in 1 quarter. The position peaked at $2.82M in Q1 2026. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Polymer Capital Management (HK) reported no remaining ArriVent BioPharma position as of Q2 2026 after selling out during the quarter.
  • Polymer Capital Management (HK) sold 122,276 ArriVent BioPharma shares in Q2 2026, an estimated $2.82M.
  • Polymer Capital Management (HK) first reported a position in ArriVent BioPharma in Q1 2026 and held it in 1 quarter.
  • Polymer Capital Management (HK)'s ArriVent BioPharma position peaked at $2.82M in Q1 2026.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Polymer Capital Management (HK)'s 13F filing for Q2 2026, filed 13 Aug 2026.